March 21, 2013 – San Francisco-based Medizone International (MZEI:OB) (MZEI:QB), announced today that its patented, peer-reviewed disinfection system is ‘more than capable’ of eliminating CRE from hospital and health care environments.

Medizone CEO Edwin Marshall stated, “Given the growing public, media and health sector interest in the emergence of CRE (Carbapenem-resistant Enterobacteriaceae) in hospitals as a highly antibiotic resistant cause of hospital acquired infections (HAI), we felt that it was important to make public the anticipated effectiveness of AsepticSure with CRE.”

Dr Michael E. Shannon M.A., M.Sc., M.D. President and Director of Medical Affairs for Medizone, added, “Although we are not permitted to conduct research on extremely dangerous pathogens such as CRE, I can say unequivocally that we have absolutely no difficulty destroying all of its relatives including Klebsiella and E coli which are commonly cited as examples of Enterobacteriaceae.

“These bacteria are among the easiest for our AsepticSure system to eliminate in that when we achieve a 6 log (99.9999%) kill with MRSA we are usually looking at a 7 log kill for Klebsiella and E coli (99.99999%). I therefore have no doubt that CRE can be completely eradicated from any contaminated space using our AsepticSure system.”

AsepticSure has recently been trialed successfully at Belleville General Hospital in Ontario, Canada, and is also the recipient of a prestigious WHO award for innovation.

For press information on Medizone International, please contact:

Bruce Smeaton, Investor Relations, Medizone International, Inc.

T: 001-415-331-0202 E: bruce@medizoneint.com

Medizone International, Inc. is engaged in initial production and sales of its modular design AsepticSure ® Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.